These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 18155906)

  • 1. Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors.
    Park WK; Kennedy RM; Larsen SD; Miller S; Roth BD; Song Y; Steinbaugh BA; Sun K; Tait BD; Kowala MC; Trivedi BK; Auerbach B; Askew V; Dillon L; Hanselman JC; Lin Z; Lu GH; Robertson A; Sekerke C
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1151-6. PubMed ID: 18155906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thermodynamic and structure guided design of statin based inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
    Sarver RW; Bills E; Bolton G; Bratton LD; Caspers NL; Dunbar JB; Harris MS; Hutchings RH; Kennedy RM; Larsen SD; Pavlovsky A; Pfefferkorn JA; Bainbridge G
    J Med Chem; 2008 Jul; 51(13):3804-13. PubMed ID: 18540668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors.
    Pfefferkorn JA; Song Y; Sun KL; Miller SR; Trivedi BK; Choi C; Sorenson RJ; Bratton LD; Unangst PC; Larsen SD; Poel TJ; Cheng XM; Lee C; Erasga N; Auerbach B; Askew V; Dillon L; Hanselman JC; Lin Z; Lu G; Robertson A; Olsen K; Mertz T; Sekerke C; Pavlovsky A; Harris MS; Bainbridge G; Caspers N; Chen H; Eberstadt M
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4538-44. PubMed ID: 17574412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase.
    Bratton LD; Auerbach B; Choi C; Dillon L; Hanselman JC; Larsen SD; Lu G; Olsen K; Pfefferkorn JA; Robertson A; Sekerke C; Trivedi BK; Unangst PC
    Bioorg Med Chem; 2007 Aug; 15(16):5576-89. PubMed ID: 17560788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly stereoselective hydrogenations--as key-steps in the total synthesis of statins.
    Andrushko N; Andrushko V; Tararov V; Korostylev A; König G; Börner A
    Chirality; 2010 May; 22(5):534-41. PubMed ID: 19899159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of novel, conformationally restricted HMG-CoA reductase inhibitors.
    Pfefferkorn JA; Choi C; Song Y; Trivedi BK; Larsen SD; Askew V; Dillon L; Hanselman JC; Lin Z; Lu G; Robertson A; Sekerke C; Auerbach B; Pavlovsky A; Harris MS; Bainbridge G; Caspers N
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4531-7. PubMed ID: 17574411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies.
    Pasha MK; Muzeeb S; Basha SJ; Shashikumar D; Mullangi R; Srinivas NR
    Biomed Chromatogr; 2006 Mar; 20(3):282-93. PubMed ID: 16143964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemia.
    Pfefferkorn JA; Choi C; Larsen SD; Auerbach B; Hutchings R; Park W; Askew V; Dillon L; Hanselman JC; Lin Z; Lu GH; Robertson A; Sekerke C; Harris MS; Pavlovsky A; Bainbridge G; Caspers N; Kowala M; Tait BD
    J Med Chem; 2008 Jan; 51(1):31-45. PubMed ID: 18072721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: The CENTAURUS trial design.
    Lablanche JM; Danchin N; Farnier M; Tedgui A; Vicaut E; Alonso J; Crean P; Leone A; Morais J; Santini M; Licour M; Farah M; Tardif JC
    Arch Cardiovasc Dis; 2008 Jun; 101(6):399-406. PubMed ID: 18809153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statin, the black box.
    Hatem S; Boccara F
    Arch Cardiovasc Dis; 2008 Jun; 101(6):377-9. PubMed ID: 18809149
    [No Abstract]   [Full Text] [Related]  

  • 11. Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression.
    Kah J; Wüstenberg A; Keller AD; Sirma H; Montalbano R; Ocker M; Volz T; Dandri M; Tiegs G; Sass G
    Oncol Rep; 2012 Sep; 28(3):1077-83. PubMed ID: 22710979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of statins on glucose metabolism--a matter of debate.
    Anagnostis P; Athyros VG; Karagiannis A; Mikhailidis DP
    Am J Cardiol; 2011 Jun; 107(12):1866. PubMed ID: 21640222
    [No Abstract]   [Full Text] [Related]  

  • 13. Not all statins interfere with clopidogrel during antiplatelet therapy.
    Mach F; Senouf D; Fontana P; Boehlen F; Reber G; Daali Y; de Moerloose P; Sigwart U
    Eur J Clin Invest; 2005 Aug; 35(8):476-81. PubMed ID: 16101667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells.
    Verhulst A; D'Haese PC; De Broe ME
    J Am Soc Nephrol; 2004 Sep; 15(9):2249-57. PubMed ID: 15339974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statins and glycaemic control--a cause for concern?
    Hitman GA
    Diabet Med; 2012 May; 29(5):557. PubMed ID: 22506936
    [No Abstract]   [Full Text] [Related]  

  • 16. Binding thermodynamics of statins to HMG-CoA reductase.
    Carbonell T; Freire E
    Biochemistry; 2005 Sep; 44(35):11741-8. PubMed ID: 16128575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The human primary hepatocyte transcriptome reveals novel insights into atorvastatin and rosuvastatin action.
    Hafner M; Juvan P; Rezen T; Monostory K; Pascussi JM; Rozman D
    Pharmacogenet Genomics; 2011 Nov; 21(11):741-50. PubMed ID: 21869732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyrazole inhibitors of HMG-CoA reductase: an attempt to dramatically reduce synthetic complexity through minimal analog re-design.
    Larsen SD; Poel TJ; Filipski KJ; Kohrt JT; Pfefferkorn JA; Sorenson RJ; Tait BD; Askew V; Dillon L; Hanselman JC; Lu GH; Robertson A; Sekerke C; Kowala MC; Auerbach BJ
    Bioorg Med Chem Lett; 2007 Oct; 17(20):5567-72. PubMed ID: 17764936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do the lipid responses to rosuvastatin and atorvastatin differ between Chinese and Caucasians? Comparison of the DISCOVERY-Hong Kong study with other DISCOVERY studies.
    Hu M; Lui SS; Ko GT; Tomlinson B
    Int J Cardiol; 2013 Oct; 168(3):3071-3. PubMed ID: 23642826
    [No Abstract]   [Full Text] [Related]  

  • 20. Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-treated mice and increases exercise endurance.
    Muraki A; Miyashita K; Mitsuishi M; Tamaki M; Tanaka K; Itoh H
    J Appl Physiol (1985); 2012 Aug; 113(3):479-86. PubMed ID: 22653988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.